TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Coccinia Cordifolia Extract on Blood Sugar of Newly Diagnosed Diabetics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients with clinical Diagnosis of Type 2 diabetes requiring only behavioral or lifestyle intervention.~2. Fasting blood glucose in the range of 110-180 mg/dl~3. Age range - 35 to 60 years~4. Willing to participate in the study and perform all measurements~Exclusion Criteria:~1. Presence of any chronic disease or organ failure~2. Concurrent use of medication to control blood glucose levels

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed diagnosis of T2DM by standard criteria~2. Patients who have received a stable dose of SU for at least 12 weeks prior to Visit 1~3. HbA1c ≥7.5% to ≤ 11.0% at Visit 1 and Visit 3 (Week -1)~4. Age: ≥18 to ≤ 80 years at Visit 1.~5. BMI ≥ 20 and ≤ 40 kg/m\^2 at visit 1.~Exclusion Criteria:~1. FPG ≥ 270mg/dl (15.0 mmol/L) at Visit 1 or Visit 3 (Week -1)~2. Severe or repetitive hypoglycemia, as defined in section 3.1, during the run-in period (between Visit 2 and Visit 4)~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- vildagliptin (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic pulmonary embolism with or without symptomatic deep vein thrombosis~Exclusion Criteria:~* End stage renal failure, hepatic failure, uncontrolled hypertension;~* Active bleeding or high risk for bleeding;~* Pregnancy or childbearing potential without proper contraceptive measures, threatened abortion.~* Breastfeeding.~* Known allergy to idraparinux or idrabiotaparinux, avidin or egg proteins;~* hypersensitivity to warfarin, enoxaparin, heparin or pork product; or any other contraindication listed in the labelling of warfarin or enoxaparin;~* Indication of prolonged anticoagulation therapy for other reason than PE;~* Life expectancy \< 6 months;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Idrabiotaparinux (Type: EXPERIMENTAL): Idrabiotaparinux sodium, 3.0 mg, once-weekly for 3 or 6 months depending on the stratum, after enoxaparin, 1.0 mg/kg, every 12 hours for at least 5 days.~Avidin, 100 mg, at the discretion of the investigator whenever deemed appropriate and possible (ie, life-threatening bleeding, emergency invasive procedure with the potential of uncontrolled bleeding, or over-dosage).
- Warfarin (Type: ACTIVE_COMPARATOR): Warfarin, INR-adjusted dose, started 24 hours after the start of enoxaparin, 1.0 mg/kg, every 12 hours for at least 5 days, and continued for 3 or 6 months depending on the stratum.~Avidin, 100 mg, at the discretion of the investigator whenever deemed appropriate and possible (ie, life-threatening bleeding, emergency invasive procedure with the potential of uncontrolled bleeding, or over-dosage).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 7.0

Eligibility Criteria:
Key Inclusion Criteria:~* Willing and able to provide written informed consent~* Chronic HCV infection (≥ 6 months) documented by medical history or liver biopsy~* HCV genotype 4 at screening~* HCV treatment naive or prior participation in this study or study GS-US-334-0138 (Cohorts 1 and 2 only)~* Cohort 3 only: HCV treatment-experienced (previously received therapy for HCV infection with an interferon (IFN)-containing regimen, with or without RBV and/or an HCV NS3/NS4A protease inhibitor (PI)~* Body mass index (BMI) ≥ 18 kg/m\^2~* Screening laboratory values within defined thresholds~* Use of effective protocol-approved contraception methods~Key Exclusion Criteria:~* History of clinically-significant illness or any other major medical disorder that may interfere with treatment, assessment or compliance with the protocol~* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~* Pregnant or nursing females or male with pregnant female partner~* Clinically-relevant drug or alcohol abuse within 12 months of screening~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF 8 wk TN (Cohort 1, Group 1) (Type: EXPERIMENTAL): LDV/SOF for 8 weeks (treatment-naive (TN))
- LDV/SOF+RBV 8 wk TN (Cohort 1, Group 2) (Type: EXPERIMENTAL): LDV/SOF+RBV for 8 weeks (treatment-naive)
- LDV/SOF 12 wk TN (Cohort 1, Group 3) (Type: EXPERIMENTAL): LDV/SOF for 12 weeks (treatment-naive)
- LDV/SOF+RBV 12 wk TN (Cohort 1, Group 4) (Type: EXPERIMENTAL): LDV/SOF+RBV for 12 weeks (treatment-naive)
- LDV/SOF+RBV 12 wk TE (Cohort 2) (Type: EXPERIMENTAL): Treatment-experienced (TE) participants who completed treatment in Gilead sponsored study GS-US-334-0138 or in Cohort 1 of this study and did not achieve SVR12 will receive LDV/SOF+RBV for 12 weeks.
- LDV/SOF 12 wk TE (Cohort 3, Group 1) (Type: EXPERIMENTAL): LDV/SOF for 12 weeks (treatment-experienced)
- LDV/SOF+RBV 12 wk TE (Cohort 3, Group 2) (Type: EXPERIMENTAL): LDV/SOF+RBV for 12 weeks (treatment-experienced)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed presence of thrombocytopenia with platelet count \< 30,000/mm3 at the pre-dose visit.~* History of isolated ITP~* RhD-positive serology.~* Previous treatment and response to first line therapy for ITP~Exclusion Criteria:~* Known clinical picture suggestive of other causes of thrombocytopenia, especially systematic lupus erythematosus,antiphospholipid syndrome, Evans syndrome, immunodeficiency states, lymphoproliferative disorders, liver disease,ingestion of drugs such as quinidine/quinine, heparin and sulfonamides and hereditary thrombocytopenia confirmed by relevant laboratory findings.~* Suspected infection with HIV, Hepatitis C, H. pylori.~* Clinical splenomegaly~* History of abnormal bone marrow examination.~* Ongoing haemorrhage corresponding to a grade 3 or 4 on the WHO bleeding scale.~* Underlying haemolytic condition~* History of splenectomy.~* Subject is pregnant, breast feeding or intends to become pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Patients treated with Sym001

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must sign an Institutional Review Board (IRB) approved written informed consent for this study.~* Male and female 18 years of age and older.~* Participants must have clinical diagnosis of moderate to severe rosacea.~* Have a minimum total of 15 and a maximum of 70 total inflammatory lesions (papules and/or pustules) including those present on the nose.~* Have 2 nodules or less.~Exclusion Criteria:~* Females, who are pregnant, breastfeeding, or planning a pregnancy within the period of their study participation or were found to have positive pregnancy test at Baseline or screening visits.~* Presence of more than 2 facial nodules or any nodule greater than 1 centimeter (cm).~* Current or past ocular rosacea (for example, conjunctivitis, blepharitis, or keratitis) of sufficient severity to require topical or systemic antibiotics.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Study Drug (Type: EXPERIMENTAL): Daily Encapsulated Benzoyl Peroxide (E-BPO) Cream, for 8 weeks (period 1). Subjects will then switch treatments to the vehicle cream for a period of 4 weeks (period 2),
- Vehicle (Type: PLACEBO_COMPARATOR): Daily Vehicle Cream, for 8 weeks (period 1). Subjects will then switch treatments to the study drug encapsulated E-BPO for a period of 4 weeks (period 2),

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of a 6% Hydrogen Peroxide Tooth Bleaching Agent

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age over 18 years (both sexes)~* 6 present upper front teeth~* No caries~* No restorations (anterosuperior group)~* No previous whitening treatments~* Tooth color value of A3 or less (Vita Classical scale), which was determined with a spectrophotometer (Vita Easy Shade® Compact) on the middle third of the vestibular surface of the maxillary lateral incisors~Exclusion Criteria:~* Pregnant or nursing mothers~* In pharmacological treatment~* Bruxism and patients who reported prior tooth sensitivity~* Previous tooth whitening (either at home or professionally)~* Visible dental cracks, developmental defects or teeth stained by tetracycline or fluorosis in the anterosuperior group~* Treatment with fixed appliances~* Periodontal disease or cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 37.5% gel (Type: ACTIVE_COMPARATOR): 37.5% gel to bleach teeth
- 6% gel (Type: EXPERIMENTAL): 6% gel to bleach teeth

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hostile Interpretation Bias Training to Treat Irritability

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adolescents in mental health treatment, with at least:~  1. mild, clinically significant irritability, and~ 2. typical intellectual functioning (IQ\>80)~Exclusion Criteria:~* Any of the following mental health diagnoses:~  1. current post-traumatic stress~ 2. lifetime bipolar I or II disorder~ 3. lifetime cyclothymic disorder~ 4. lifetime psychotic disorder~ 5. lifetime autism spectrum disorder~* Major medical problems, including head trauma.~* MRI-specific safety exclusions for the MRI arms.~* Clinical instability.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Active IBT, Out of MRI (Type: ACTIVE_COMPARATOR): Interpretation bias training where participants learn more positive judgements of ambiguous facial expressions relative to their own baseline bias. This arm is completed in the clinic.
- Sham IBT, Out of MRI (Type: SHAM_COMPARATOR): Interpretation bias training where participants' baseline judgements of ambiguous facial expressions is reinforced. This arm is completed in the clinic.
- Active IBT, In MRI (Type: ACTIVE_COMPARATOR): Interpretation bias training where participants learn more positive judgements of ambiguous facial expressions relative to their own baseline judgments. This arm is completed in a magnetic resonance imaging machine.
- Sham IBT, In MRI (Type: SHAM_COMPARATOR): Interpretation bias training where participants' baseline judgements of ambiguous facial expressions is reinforced. This arm is completed in a magnetic resonance imaging machine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PRecision Interventions for SMoking in the SCCS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Daily smoker of ≥5 cigarettes per day (CPD)~* Enrolled participant of the Southern Community Cohort Study (SCCS) who completed a prior survey indicating they were willing to be contacted regarding a smoking cessation clinical trial~* Residence in Tennessee (TN) or Mississippi (MS)~* Has stored blood sample with the SCCS~* Has established primary care provider (PCP)~* Medically eligible and willing to take varenicline and NRT~Exclusion Criteria:~* Currently taking medication to quit smoking~* enrolled, or planning to be enrolled, in another smoking cessation program~* Inability to give informed consent or participate due to cognitive disorder (e.g., dementia, severe intellectual disability)~* Unstable psychiatric illness (ER or hospitalized for psychiatric condition in past 6 months, change in psychiatric medications in past 3 months, or suicidal ideation in past 6 months)~* not able to send or receive mail~* no access to a telephone or inability to communicate by telephone~* unable to speak and read English~* history of seizures or Buerger's disease~* currently pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Guideline-Based Care (GBC) (Type: OTHER): GBC participants are 1) referred to the state quitline, 2) provided the NCI Clearing the Air smoking cessation program, and 3) asked to talk to their healthcare provider about potential lung cancer screening (LCS). Medication assignment is guided by standard guidelines and a conversation between the study tobacco counselor and the participant. Groups 1 and 2 also receive GBC counseling.
- Nicotine Metabolite Ratio (PC-NMR) (Type: ACTIVE_COMPARATOR): Group 1, nicotine metabolism. Medication is guided by nicotine metabolism.
- Respiragene (PC-Respiragene) (Type: ACTIVE_COMPARATOR): Group 2, genetically-informed lung cancer risk score. Medication assignment is guided by standard guidelines and a conversation between the study nurse and the participant.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improvement of Sensibility in the Foot in Diabetic Patients Induced by EMLA-application to the Lower Leg

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (18-75 years) suffering from diabetes with subjective sensory impairment in the sole of the foot.~Exclusion Criteria:~* Patients with painful neuropathy or established ulcer formation in toes or sole of the foot, known hypersensitivity to local anaesthetics, major vascular reconstructions, communication problems due to severe language problems.~* Patients with pacemakers or magnetic implants or suffering from claustrophobia will not be subjected to fMRI-investigation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- EMLA cream (Type: EXPERIMENTAL): None
- Placebo cream (Type: PLACEBO_COMPARATOR): A placebo cream identical in appearance and consistency to the experimental cream

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Principal Inclusion Criteria:~* Subject must be 18 to 75 years of age.~* Documented physician-diagnosed asthma for at least 12 months.~* Subjects who have received a physician- prescribed asthma controller medication with medium or high dose ICS for at least 12 months; must be stable for at least 3 months prior to screening visit.~* At least one additional maintenance asthma controller medication is required according to standard practice of care and must be documented for at least 3 months.~* At enrolment, the subject must have a predicted normal value for the morning pre-bronchodilator FEV1\>50% and more than 1L.~* Evidence of asthma as documented by reversibility of FEV1 ≥12% and ≥200 mL in the previous 12 months prior to screening, or during the screening period prior to randomization.~* ACQ-6 score ≥ 1.5 during the screening period prior to randomization.~Principal Exclusion Criteria:~* Any clinically important pulmonary disease other than asthma.~* History of cancer.~* Hospitalization or required OCS for asthma exacerbation within 6 weeks of enrolment or \>3 exacerbations requiring OCS or hospitalization in the year prior to visit 1 or who had been intubated or admitted to ICU for asthma exacerbation in the year prior to enrolment.~* History of a clinically significant infection, including upper (URTI) or lower respiratory tract infection (LRTI), requiring treatment with antibiotics or antiviral medications finalized \<2 weeks before visit 1 or during the run-in period.~* Current smokers or subjects with smoking history ≥10 pack-yrs, including e-cigarettes. Former smokers with a smoking history of \<10 pack-yrs must have stopped for at least 6 months prior to visit 1, including e-cigarette use.~* History of chronic alcohol or drug abuse within 12 months prior to visit 1.~* Tuberculosis requiring treatment within 12 months prior to visit 1.~* History of known immunodeficiency disorder including a positive HIV test at visit 1, or the subject is taking antiretroviral medications as determined by medical history and/or subject's verbal report.~* History of anaphylaxis or documented immune complex disease (type III hypersensitivity reactions) following any biologic therapy Subject randomized in a previous Tezepelumab study or in a current study with another investigational product.~* Pregnant, breastfeeding or lactating women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Tezepelumab (Type: EXPERIMENTAL): Tezepelumab subcutaneous injection
- Placebo (Type: PLACEBO_COMPARATOR): Placebo subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Nebulized Dexmedetomidine for Treatment of Obstetric Post-Dural Puncture Headache

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Post-partum females diagnosed with PDPH after elective caesarean section under spinal anesthesia and with visual analogue score (VAS) ≥ 4 and Lybecker et al. classification score ≥2.~* Age 21- 40 years old.~* ASA I and ASA II.~* Accepted mental state of the patient.~Exclusion Criteria:~* Patient refusal.~* ASA Grade III and IV.~* Emergent caesarean section.~* Inadequate temporal window.~* Hypertensive disorders of the pregnancy.~* Atrial fibrillation.~* History of allergy to local anesthetics.~* History of chronic headache, migraine, convulsions, and cerebrovascular accident.~* Contraindication to spinal anesthesia: coagulopathy, infection at site of injection

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: PLACEBO_COMPARATOR): received ultrasonic nebulization of 4mL 0.9% saline twice daily for 3 days
- Dexmedetomidine group (Type: ACTIVE_COMPARATOR): received ultrasonic nebulization of 1 µg/kg dexmedetomidine diluted in 4mL 0.9% saline twice daily for 3 days. The intervention will be continued until achieving a VAS score ≤3 and Lybecker et al. classification score \<2 and or for a maximum of 72 hours. Patients in this group who achieved the target scores before 72 hours will be given 4ml of saline 0.9% nebulization to maintain blinding.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete